Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma Colorectal cancer (CRC) remains a major global health burden, being ...
Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with ...
The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...
MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2–Altered ...
Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In recent ...
In patients with relapsed or refractory systemic lupus erythematosus, allogeneic CAR-NK cell therapy may offer a safe ...
About PromiCell, Inc. PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed ...
Morning Overview on MSN
Scientists find a way to turbocharge cancer-fighting immunity
Cancer immunotherapy has already transformed treatment for some patients, yet too often the body’s defenders stall out before ...
Within tumors in the human body, there are immune cells (macrophages) capable of fighting cancer, but they have been unable ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback